ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
The purpose of the run-in phase of this study is to determine the appropriate and tolerable dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment. The purpose of the randomized phase of this study is to determine the efficacy of ZD6474 alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of paclitaxel and carboplatin alone in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment.
Checked against the public recordLast updated Aug 25, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Genzyme, a Sanofi Company
- Interventions being studied
- Drug: ZD6474; Drug: Paclitaxel; Drug: Carboplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Signed informed consent * 18 years or older * Histologically or cytologically confirmed locally advanced or metastatic NSCLC * No prior chemotherapy/biological therapy/radiation therapy * One or more measurable lesions * Life expectancy more than 12 weeks Exclusion Criteria: * Brain metastases or spinal cord compression * Currently active skin disease * History of significant hemoptysis * Abnormal blood chemistry * Cardiac abnormalities * Recent significant cardiac event * Coexisting malignancies
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteConcord, California
- Research SiteLos Angeles, California
- Research SiteChicago, Illinois
- Research SiteBoston, Massachusetts
- Research SiteSt Louis, Missouri
- Research SiteProvidence, Rhode Island
- Research SiteNashville, Tennessee
- Research SiteAustin, Texas
- Research SiteHouston, Texas
- Research SiteLubbock, Texas
- Research SiteNorfolk, Virginia
- Research SiteSeattle, Washington
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2016. Always confirm current availability with the study team.